DOCSLIB.ORG

Prognosticfactors in Patientswith Advancedstage Prostatecancer1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prognosticfactors in Patientswith Advancedstage Prostatecancer1 [CANCER RESEARCH 45, 5173-5179, October 1985] PrognosticFactorsin Patientswith AdvancedStage ProstateCancer1 Lawrence J. Emrich, Roger L. Priore, Gerald P. Murphy, Mark F. Brady,2 and the Investigators of the National Prostatic Cancer Project3 Department of Biomathematics [L J. E, R L P.], the National Prostatic Cancer Project Headquarters Office [G. P. M.¡,and the National Prostatic Cancer Project Statistical Office [M. F. B.], Roswell Park Memorial Institute, Buffalo, New York 14263 ABSTRACT protocols since 1973 (Table 1). Details concerning the treatment regi mens used in these protocols, together with comparisons of the various The relationships of 13 potential prognostic factors to objective regimens, have been discussed previously (2-11). response to treatment and survival time were investigated, using Information gathered on the patients at the time of entry into group data gathered on 1,020 patients with advanced stage prostate protocols included the factors listed in Table 2. These 13 variables were cancer who have participated in the clinical trials of the National thought to be among the most important prognostic factors for advanced Prostatic Cancer Project. Multivariate statistical analyses re stage disease. One thousand, six hundred one (83%) of the patients vealed that previous hormone response status, analgesics, pain, were évaluablefor objective response to treatment, and 1020 (64%) of these 1601 patients had information recorded for all 13 of the factors elevated acid phosphatase, and anemia were the important, (Table 1). This report is restricted to these 1020 patients. independent prognostic factors for objective response to treat Definition of Prognostic Variables and End Points. Each of the ment. For survival time, the significant prognostic factors were potential prognostic variables listed in Table 2 was treated as a categor previous hormone response status, anorexia, elevated acid ical variable in all analyses, with categories defined as follows. Previous phosphatase, pain, elevated alkaline phosphatase, obstructive hormone response was classified as a failure if the disease was in symptoms, tumor grade, performance status, anemia, and age progression after hormonal or ablative therapy (3-5, 7-11), as stable if at diagnosis. It is recommended that future treatment protocols the disease had been stabilized by orchiectomy or hormone therapy for for advanced stage prostate cancer take into account hetero at least 3 mo (2), or as previously untreated. Performance status was geneity of the treatment groups with respect to these factors, classified as normal activity, symptomatic but ambulatory, in bed less than 50% of the time, in bed more than 50% of the time, or 100% either through the design of the protocol, or at the time of bedridden. Pain was classified as no pain, mild (occasional use of analysis. analgesics), moderate (controlled use of analgesics), or severe (uncon trollable pain). Tumor grade was classified as I, II, III, or IV, according to INTRODUCTION published criteria (12,13). Age of the patient was classified as less than or equal to 60, 61-65, 66-70, or greater than 70. The remaining factors Prostatic carcinoma is one of the most common forms of listed in Table 2 were classified as either yes or no according to whether cancer and a leading cause of cancer deaths of males in the the condition was present or absent, respectively. United States (1). Prognosis, as measured by objective response NPCP response criteria (2) were used to evaluate objective response to treatment and survival time, is known to be particularly poor to treatment as being either objective progression (treatment failure), for patients with advanced (Stage Oil) disease, as compared objectively stable, partial response, or complete response (treatment with patients with early stage disease. However, little is known success). about which factors within the former group of patients are most Survival time was measured from the time of randomization to death from any cause. important with regard to prognosis. Such knowledge is invaluable Statistical Methods. The prognostic importance of the 13 variables for planning and analyzing the results of future clinical trials with respect to objective response to treatment was assessed using a involving advanced stage patients and for assessing the prog linear logistic regression model (14). First, each variable was assessed nosis of individual patients. separately for its prognostic importance (univariate analyses). Then, to This paper presents the results of a detailed, mult ivariate study the relative prognostic importance of the variables, a forward statistical study of prognostic factors in patients with advanced selection procedure was used to develop a multivariate model which stage prostate cancer. included all prognostic factors which, after adjusting for the effects of all factors entered into the model previously, were found to be significantly (P value less than 0.05) related to objective response. MATERIALS AND METHODS The prognostic importance of the 13 factors with respect to survival time was assessed using Cox's proportional hazards regression model Patient Population. One thousand, nine hundred forty patients with advanced stage prostatic carcinoma have been entered into NPCP4 (15). Again, each factor was assessed separately for its prognostic importance, and then a forward selection procedure was used to develop 1This work was supported in part by Research Grants CA16056, CA37010, a multivariate model. and CA34903 awarded by the National Cancer Institute. Estimates of survival time distribution curves were obtained by the 2 To whom requests for reprints should be addressed. 3 Investigators of the National Prostatic Cancer Project include Edson Pontes, method of Kaplan and Meier (16). Roswell Park Memorial Institute; Raju Thomas, Tulane Medical Center; Robert P. All P values correspond to likelihood ratio tests of hypotheses for Gibbons, The Mason Clinic; Stefan A. Loening, University of Iowa Hospitals and regression coefficients of zero. A P value of 0.05 or less was considered Clinics; David G. McLeod. Walter Reed Army Medical Center; Jean B. deKemion, to be statistically significant. University of California at Los Angeles; James M. Pierce, Jr., Wayne State Univer sity; George R. Prout, Jr., Massachusetts General Hospital; Peter T. Scardino, Baylor University; Joseph D. Schmidt, University of California at San Diego; William W. Scott, Johns Hopkins Hospital; Mark S. Sotoway, University of Tennessee; RESULTS Patrick Guiñan,Cook County Hospital; Robert C. Ranigan, University of Kentucky Medical Center; Hugh Fisher, Albany Medical College Hospital; and Douglas E. Objective Response. The results of the univariate analyses Johnson, M. D. Anderson Hospital. 4 The abbreviation used is: NPCP, National Prostatic Cancer Project. of the prognostic importance of the 13 factors with respect to Received 1/22/85; revised 4/25/85; accepted 7/11/85. objective response to treatment are summarized in Table 3. With CANCER RESEARCH VOL. 45 OCTOBER 1985 5173 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1985 American Association for Cancer Research. PROGNOSTIC FACTORS IN PROSTATE CANCER Table 1 Patient population summary NPCP treatment entered used protocol100TreatmentregimensCyclophosphamide responseFailureYractivated1973Yrclosed1975No.on protocol125No.in analyses57 (6f 5-Fluorouracil Standard treatmentHormone 200 Estramustine phosphate Failure 1974 1976 125 59(6) Streptozotocin Standard treatment 300 imidazole-carboxamide Failure 1975 1977 165 78(8) Procarbazine Cyclophosphamide 400 Prednimustine Failure 1976 1977 135 63(6) Prednimustine + estramustine 500 Diethylstilbestrol or orchiectomy Newly 1976 1980 301 131 (13) Diethylstilbestrol + cyclophos- diagnosed phamide Estramustine phosphate 600 Diethylstilbestrol Stable 1976 1982 188 100(10) Diethylstilbestrol + Cyclophos phamide Diethylstilbestrol + estramustine phosphate 700 Hydroxyurea Failure 1977 1979 125 66(6) Methyl-chloroethyl-cyclohexy- nitrosourea Cyclophosphamide 800 Estramustine phosphate Failure 1977 1979 121 56(5) Vincristine Estramustine phosphate + vin- cristine 1100 Estramustine phosphate Failure 1979 1981 189 130(13) Methotrexate cis-Platinum 1200 Estramustine phosphate Failure 1979 1981 149 96(9) c/s-Platinum Estramustine phosphate + c/s- platinum 1300 Diethylstilbestrol or orchiectomy Newly 1980 1983 317 184(18) Estramustine phosphate diagnosed Diethylstilbestrol or orchiectomy + 5-fluorouracil + Cyclophos phamide Totals 1940 1020(53) " Numbers in parentheses, percentage used in analyses. the exception of tumor grade and age of the patient, each of the categories of the factors in the model are listed in Table 5. As variables considered was found to be of prognostic importance. expected, the most important prognostic factor is previous hor Patients who are stable on hormones and patients who have mone response status (Table 4). After adjusting for the effect of failed previous hormone therapy have a poorer prognosis (i.e., a this factor, the next most important prognostic factor is whether smaller probability of a treatment success, as defined above) or not a patient requires analgesics. The remaining factors which than newly diagnosed patients, as evidenced by the negative were included in the multivariate model, in order of importance, coefficients for the "stable" and "failure" categories shown in are pain, elevated acid phosphatase, and anemia. Table 3. Prognosis improves with improved
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Resistance to Antifolates
    Oncogene (2003) 22, 7431–7457 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc Resistance to antifolates Rongbao Zhao1 and I David Goldman*,1 1Departments of Medicine and Molecular, Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA The antifolates were the first class of antimetabolites to the kinetics of the interaction between MTX and DHFR enter the clinics more than 50 years ago. Over the was fully understood, and not until the late 1970s and following decades, a full understanding of their mechan- early 1980s when polyglutamate derivatives of MTX were isms of action and chemotherapeutic potential evolved detected and their pharmacologic importance clarified. along with the mechanisms by which cells develop Likewise, an understanding of tumor cell resistance to resistance to these drugs. These principals served as a antifolates evolved slowly, often paralleling the emergence basis for the subsequent exploration and understanding of of new molecular concepts. As the mechanisms of the mechanisms of resistance to a variety of diverse resistance to antifolates were characterized, this provided antineoplastics with different cellular targets. This section insights and principles that were broadly applicable to describes the bases for intrinsic and acquired antifolate other antineoplastics. Ultimately, this knowledge led to the resistance within the context of the current understanding development of a new generation of antifolates, in the late of the mechanisms of actions and cytotoxic determinants 1980s and 1990s, which are potent direct inhibitors of of these agents. This encompasses impaired drug transport tetrahydrofolate (THF)-cofactor-dependent enzymes. Sev- into cells, augmented drug export, impaired activation of eral of these drugs are now in clinical trials, and the antifolates through polyglutamylation, augmented hydro- activity of one, pemetrexed, has been confirmed in a large lysis of antifolate polyglutamates, increased expression Phase III trial (Vogelzang et al., 2003).
    [Show full text]
  • Procarbazine
    Procarbazine DRUG NAME: Procarbazine SYNONYM(S): COMMON TRADE NAME(S): MATULANE® CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Procarbazine is a cell cycle phase-nonspecific1 pro-drug and derivative of hydrazine whose mechanism of action has not yet been clearly defined. Procarbazine may act by inhibiting protein, RNA, and DNA synthesis,2-4 and by causing free-radical damage to DNA and inhibition of mitosis.3,5 Procarbazine also has monoamine oxidase (MAO) inhibiting properties2,3 and is an immunosuppressive agent.2 Cross resistance with other chemotherapy agents has not been demonstrated.2 PHARMACOKINETICS: Oral Absorption rapid and complete; peak plasma concentration in 1 h Distribution rapid distribution including into liver, kidneys, intestinal wall, and skin3 cross blood brain barrier? yes volume of distribution no information found plasma protein binding no information found Metabolism complex spontaneous chemical decomposition and biotransformation to active metabolites,3,6 primarily in the liver3 via cytochrome P450 oxidoreductase and mitochondrial monoamine oxidase7 active metabolite(s)3,5,6,8 yes; including azo-and methylazoxy-metabolites and hydrogen peroxide inactive metabolite(s)2,9 yes; including N-isopropyl-terephthalmamic acid Excretion primarily hepatic with some renal2,3 and pulmonary10 elimination urine2-4 25-70% in 24 h primarily as N-isopropyl- terephthalmamic acid; <5-20% unchanged feces7 minimal terminal half life3,4
    [Show full text]
  • Methotrexate / Vincristine / Leucovorin / Procarbazine (Cycles 1,3,5)
    Protocol Index IP DEANGELIS WITH RITUXIMAB - METHOTREXATE / VINCRISTINE / LEUCOVORIN / PROCARBAZINE (CYCLES 1,3,5) Types: ONCOLOGY TREATMENT Synonyms: PRIMARY, CENTRAL, CNS, LYMPH, MTX, ONCOV, METHOT, VINCR, PROCARB, DEANGELIS, DEAN, RITUX Cycle 1 Repeat 1 time Cycle length: 14 days Day 1 Perform every 1 day x1 Labs ☑ COMPREHENSIVE METABOLIC PANEL Interval: Once Occurrences: -- ☑ CBC WITH PLATELET AND DIFFERENTIAL Interval: Once Occurrences: -- ☑ MAGNESIUM LEVEL Interval: Once Occurrences: -- ☑ LDH Interval: Once Occurrences: -- ☑ URIC ACID LEVEL Interval: Once Occurrences: -- ☑ PHOSPHORUS LEVEL Interval: Once Occurrences: -- Labs ☑ METHOTREXATE LEVEL Interval: Once Occurrences: -- ☑ PH, URINALYSIS Interval: Conditional Occurrences: -- Frequency Comments: Draw prior to starting Methotrexate and PRN until pH GREATER than 7. Then draw urine pH every day until MTX is LESS than 0.05 Provider Communication ONC PROVIDER COMMUNICATION 58 Interval: Once Occurrences: -- Comments: Prior to beginning Rituxan infusion, please check if a Hepatitis B and C serology has been performed within the past 6 months. Hepatitis B and C serologies results: Push F2:11554001 drawn on ***. Provider Communication ONC PROVIDER COMMUNICATION 5 Interval: Once Occurrences: -- Comments: Use baseline weight to calculate dose. Adjust dose for weight gains/losses of greater than or equal to 10%. Provider Communication ONC PROVIDER COMMUNICATION 12 Interval: Until Occurrences: -- discontinued Comments: Careful monitoring of pulmonary function tests should be performed prior
    [Show full text]
  • Cladribine Injection
    PRODUCT MONOGRAPH PrCLADRIBINE INJECTION Solution for Intravenous Injection 1 mg/mL USP Antineoplastic / Chemotherapeutic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 June 9, 2015 Toronto, ON M9W 0C8 Control No.: 181078 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 11 OVERDOSAGE ....................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 14 STORAGE AND STABILITY ................................................................................................
    [Show full text]
  • VINBLASTINE-VINCRISTINE (Chlvpp-EVA
    Chemotherapy Protocol LYMPHOMA CHLORAMBUCIL-DOXORUBICIN-ETOPOSIDE-PREDNISOLONE-PROCARBAZINE- VINBLASTINE-VINCRISTINE (ChlVPP-EVA) Regimen • Lymphoma – ChlVPP-EVA-Chlorambucil-Doxorubicin-Etoposide-Prednisolone- Procarbazine-Vinblastine-Vincristine Indication • Hodgkin’s Lymphoma Toxicity Drug Adverse Effect Chlorambucil Gastro-intestinal disturbance Doxorubicin Cardiomyopathy, alopecia, urinary discolouration (red) Etoposide Hypotension on rapid infusion, hyperbilirubinaemia Weight gain, gastro-intestinal disturbances, hyperglycaemia, Prednisolone CNS disturbances, cushingoid changes, glucose intolerance Procarbazine Insomnia, ataxia, hallucinations, headache Vinblastine Peripheral neuropathy, constipation, jaw pain, ileus Vincristine Peripheral neuropathy, constipation, jaw pain, ileus The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Patients diagnosed with Hodgkin’s Lymphoma carry a lifelong risk of transfusion-associated graft versus host disease (TA-GVHD). Where blood products are required these patients must receive only irradiated blood products for life. Local blood transfusion departments must be notified as soon as a diagnosis is made and the patient must be issued with an alert card to carry with them at all times. Monitoring Drugs • FBC, LFTs and U&Es prior to day one and eight of treatment Version 1 (May 2018) Page 1 of 10 Lymphoma- ChlVPP-EVA-Chlorambucil-Doxorubicin-Etoposide-Prednisolone-Procarbazine-Vinblastine-Vincristine Dose Modifications The dose modifications listed are for haematological, liver and renal function and limited drug specific toxicities. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped.
    [Show full text]
  • Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
    Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology Rachael R. Schulte and Richard H. Ho Department of Pediatrics, Division of Pediatric Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN (R.R.S., R.H.H.) Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 OATPs and Cancer Pharmacology Corresponding Author: Richard H. Ho, MD MSCI 397 PRB 2220 Pierce Avenue Vanderbilt University Medical Center Nashville, Tennessee 37232 Downloaded from Tel: (615) 936-2802 Fax: (615) 875-1478 Email: [email protected] molpharm.aspetjournals.org Number of pages of text: 24 Number of tables: 3 Number of figures: 1 References: 204 at ASPET Journals on September 28, 2021 Number of words: Abstract: 201 Introduction: 1386 Discussion: 7737 ABBREVIATIONS: ASBT, apical sodium dependent bile acid transporter; AUC, area under the plasma time:concentration curve; BCRP, breast cancer related protein; BSP, bromosulfophthalein; CCK-8, cholecystokinin octapeptide; DHEAS, dehydroepiandrosterone sulfate; DPDPE, [D-penicillamine2,5] enkephalin; E2G, estradiol-17ß-glucuronide; E3S, estrone-3-sulfate; ENT, equilibrative nucleoside transporter; GCA, glycocholate; HEK, human embryonic kidney; IVS, intervening sequence (notation for intronic mutations); LD, linkage disequilibrium; MATE, multidrug and toxic compound extrusion; MCT, monocarboxylate 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Process for Producing Arsenic Trioxide Formulations
    (19) TZZ_964557B_T (11) EP 1 964 557 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/285 (2006.01) A61K 33/36 (2006.01) 02.01.2013 Bulletin 2013/01 A61P 35/02 (2006.01) (21) Application number: 08075200.9 (22) Date of filing: 10.11.1998 (54) Process for producing arsenic trioxide formulations Verfahren zur Herstellung von Arsentrioxidformulierungen Procédé de production de formulations à base de trioxide d’arsenic (84) Designated Contracting States: (74) Representative: Warner, James Alexander et al AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Carpmaels & Ransford MC NL PT SE One Southampton Row London (30) Priority: 10.11.1997 US 64655 P WC1B 5HA (GB) (43) Date of publication of application: (56) References cited: 03.09.2008 Bulletin 2008/36 • KWONG Y L ET AL: "Delicious poison: Arsenic trioxide for the treatment of leukemia" BLOOD, (60) Divisional application: vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 10177319.0 / 2 255 800 3487-3488, XP002195910 • SHEN S-X ET AL: "USE OF ARSENIC TRIOXIDE (62) Document number(s) of the earlier application(s) in (AS2O3) IN THE TREATMENT OF ACUTE accordance with Art. 76 EPC: PROMYELOCITIC LEUKEMIA (APL): II. CLINICAL 98957803.4 / 1 037 625 EFFICACY AND PHARMACOKINETICS IN RELAPSED PATIENTS" BLOOD, W.B. (73) Proprietor: MEMORIAL SLOAN-KETTERING SAUNDERS, PHILADELPHIA, VA, US, vol. 89, no. CANCER CENTER 9, 1 May 1997 (1997-05-01), pages 3354-3360, New York, NY 10021 (US) XP000891715 ISSN: 0006-4971 • KONIG ET AL: "Comparative activity of (72) Inventors: melarsoprol and arsenic trioxide in chronic B - • Warrell, Raymond, P., Jr.
    [Show full text]
  • Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
    Volume 2 (2012) // Issue 1 // e-ISSN 2224-3453 Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro- oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of NeuroOncology Magazine 2012; 2 (1) 25-36 Homepage: www.kup.at/ journals/eano/index.html OnlineOnline DatabaseDatabase FeaturingFeaturing Author,Author, KeyKey WordWord andand Full-TextFull-Text SearchSearch THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY Member of the Chemotherapy and Polyneuropathies Chemotherapy and Polyneuropathies Wolfgang Grisold1, Stefan Oberndorfer2, Anthony J Windebank3 Abstract: Peripheral neuropathies induced by taxanes) immediate effects can appear, caused to be caused by chemotherapy or other mecha- chemotherapy (CIPN) are an increasingly frequent by different mechanisms. The substances that nisms, whether treatment needs to be modified problem. Contrary to haematologic side effects, most frequently cause CIPN are vinca alkaloids, or stopped due to CIPN, and what symptomatic which can be treated with haematopoetic taxanes, platin derivates, bortezomib, and tha- treatment should be recommended. growth factors, neither prophylaxis nor specific lidomide. Little is known about synergistic neu- Possible new approaches for the management treatment is available, and only symptomatic rotoxicity caused by previously given chemo- of CIPN could be genetic susceptibility, as there treatment can be offered. therapies, or concomitant chemotherapies. The are some promising advances with vinca alka- CIPN are predominantly sensory, duration-of- role of pre-existent neuropathies on the develop- loids and taxanes. Eur Assoc Neurooncol Mag treatment-dependent neuropathies, which de- ment of a CIPN is generally assumed, but not 2012; 2 (1): 25–36. velop after a typical cumulative dose. Rarely mo- clear.
    [Show full text]
  • Practical Aspects of the Use of Intrathecal Chemotherapy
    Farmacia Hospitalaria ISSN: 1130-6343 ISSN: 2171-8695 Aula Médica Ediciones (Grupo Aula Médica S.L.) Practical aspects of the use of intrathecal chemotherapy Olmos-Jiménez, Raquel; Espuny-Miró, Alberto; Cárceles-Rodríguez, Carlos; Díaz-Carrasco, María Sacramento Practical aspects of the use of intrathecal chemotherapy Farmacia Hospitalaria, vol. 41, no. 1, 2017 Aula Médica Ediciones (Grupo Aula Médica S.L.) Available in: http://www.redalyc.org/articulo.oa?id=365962303008 DOI: 10.7399/fh.2017.41.1.10616 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative REVISIONES Practical aspects of the use of intrathecal chemotherapy Aspectos prácticos de la utilización de quimioterapia intratecal Raquel Olmos-Jiménez 1 Universidad de Murcia, Spain Alberto Espuny-Miró 1 Universidad de Murcia, Spain Carlos Cárceles-Rodríguez 1 Universidad de Murcia, Spain María Sacramento Díaz-Carrasco 2 Hospital Clínico Universitario Virgen de la Arrixaca, Spain Farmacia Hospitalaria, vol. 41, no. 1, Abstract 2017 Introduction: Intrathecal chemotherapy is frequently used in clinical practice for treatment and prevention of neoplastic meningitis. Despite its widespread use, there is Aula Médica Ediciones (Grupo Aula Médica S.L.) little information about practical aspects such as the volume of drug to be administered or its preparation and administration. Received: 28 July 2016 Accepted: 15 October 2016 Objective: To conduct a literature review about practical aspects of the use of intrathecal chemotherapy. DOI: 10.7399/.2017.41.1.10616 Materials: Search in PubMed/ Medline using the terms “chemotherapy AND intrathecal”, analysis of secondary and tertiary information sources. CC BY-NC-ND Results: e most widely used drugs in intrathecal therapy are methotrexate and cytarabine, at variable doses.
    [Show full text]
  • Preoperative Medication Directive a Clinical Practice Protocol Practitioner Information
    Preoperative Medication Directive A Clinical Practice Protocol Practitioner Information Please note: this is a living document subject to change. We recommend that this not be printed but rather accessed on line for the most current information. Nov 2017 Table of Contents Regional practice protocol for Preoperative Medication Page Directives Purpose & Intent 1 Practice Outcomes 1 Background 2 Components 2 References 3 Authors 4 Guidelines- Section A (for select Nurses) 5 Guidelines- Section B (for Surgeons) 12 Guidelines- Section C (for Anaesthesiologists) pending PURPOSE AND INTENT Who this document is for: These sectioned documents are a resource and an information source for Preoperative Assessment/Anaesthesia Clinic Staff, Surgeons and Anaesthesiologists. Each Section (A, B, etc...) was created for a primary user group. Users of this document shall always employ critical thinking and seek additional guidance from the appropriate colleagues (ie: anaesthesiologist and/or surgeon/prescribing physician) when concerns or variances arise. 1. Practice Outcomes How to use this document: This tool is to supplement the practice at each site. Implementation of this document will be at the discretion of the site leaders, however the directions provided to patients regarding preoperative medications should be consistent with this document (under the consideration of critical thinking). Clinical judgment, critical thinking and patient specific needs & concerns should always be employed, considered and addressed for all parts of the document. Any care provider with a Preoperative Medication Directive medication question is asked to submit in writing the medication in question (along with any supporting evidence if available) to the PAC Working Group (chair) [email protected] for consideration.
    [Show full text]